Inoperable Stage III EGFR Mutant Non-Small Cell Lung Cancer: time for drug first, local later?

Ann Oncol. 2024 Oct 10:S0923-7534(24)04054-7. doi: 10.1016/j.annonc.2024.10.005. Online ahead of print.

Authors

A John¹, F McDonald², S Popat³

Affiliations

¹ Lung Unit, Royal Marsden Hospital, 203 Fulham Road, London, SW3 6JJ, UK.
² Lung Unit, Royal Marsden Hospital, 203 Fulham Road, London, SW3 6JJ, UK; Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK.
³ Lung Unit, Royal Marsden Hospital, 203 Fulham Road, London, SW3 6JJ, UK; Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP, UK. Electronic address: sanjay.popat@rmh.nhs.uk.

PMID: 39395537
DOI: 10.1016/j.annonc.2024.10.005

No abstract available

Keywords: EGFR; Non-small cell lung cancer; Osimertinib; Stage III; Unresectable.